8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)

April 3, 2007 (March 30, 2007)

MedImmune, Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-19131	52-1555759
(State or other jurisdiction of incorporation or organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

One MedImmune Way, Gaithersburg, MD 20878

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code (301) 398-0000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(d)           On April 2, 2007, MedImmune, Inc. (the “Company”) announced that Mr. Robert H. Hotz, co-chairman and senior managing director of Houlihan Lokey Howard & Zukin, has been appointed as a member of its Board of Directors.  Mr. Hotz was appointed by the Company’s Board of Directors effective as of March 30, 2007 and will serve on the Investment Committee and the Compensation and Stock Committee of the Board of Directors.

Mr. Hotz’s appointment as director was not made pursuant to any arrangement or understanding between Mr. Hotz and any other person.

Pursuant to the Company’s 2003 Non-Employee Directors Stock Option Plan, Mr. Hotz was granted an option to purchase 30,000 shares of the Company’s common stock at the commencement of his service on the Board of Directors.  In subsequent years, he will be entitled to receive an annual grant of an option to purchase 25,000 shares of common stock for his service on the Board of Directors.  These option grants are exercisable and vest over a four year period.  Mr. Hotz will also receive the standard annual cash retainer and meeting attendance fees paid to all non-executive directors.

A copy of the Company’s press release announcing the appointment of Mr. Hotz to the Board of Directors is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated April 2, 2007, titled “MedImmune Announces Addition of Robert H. Hotz to Board of Directors.”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MedImmune, Inc.

Date: April 3, 2007	By:	/s/ William C. Bertrand, Jr.
		William C. Bertrand, Jr.
		Senior Vice President, General Counsel & Secretary

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contacts

Media: Jamie Lacey, 301-398-4035

Investors: Beatrice Pierre, 301-398-4905

http://www.medimmune.com

MEDIMMUNE ANNOUNCES ADDITION OF ROBERT H. HOTZ
TO BOARD OF DIRECTORS

GAITHERSBURG, MD, April 2, 2007 — MedImmune, Inc. (Nasdaq: MEDI) announced today that Robert H. Hotz has been appointed to its board of directors.  He also will be appointed to the board’s investment and compensation committees.

Mr. Hotz joined Houlihan Lokey Howard & Zukin in 2002 and is currently the firm’s co-chairman, co-head of corporate finance, and senior managing director. He is also a member of Houlihan Lokey’s board of directors and the operating committee.  Previously, he was senior vice chairman of UBS and head of corporate finance for the Americas. In 1991, he joined a predecessor firm to UBS (Dillon, Read & Co. Inc.) as co-head of the corporate finance department and as a member of the firm’s operating committee and board of directors. Currently, Mr. Hotz serves on the boards of two other public companies: Universal Health Services, Inc. and PepBoys.  He is a graduate of Rutgers University and received his MBA from Cornell University.

Mr. Hotz replaces Gordon Macklin on MedImmune’s board of directors.  Mr. Macklin died in February 2007.

About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at www.medimmune.com.

# # #